Ibrance is indicated for the treatment of patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant in patients with disease progression following endocrine therapy.1

Clinical efficacy across patient groups

All subgroups studied​​​​​​​ Visceral disease Bone-only disease Elderly Pre-/peri-menopausal
In 1st or later line with fulvestrant
In PALOMA-3, IBRANCE + fulvestrant in 1st or later line demonstrated PFS improvements vs placebo + fulvestrant in pre-menopausal patients*2
  • In PALOMA-3, 21% of patients treated with IBRANCE + fulvestrant were pre-/peri-menopausal†2

Small patient numbers can be a limitation of subgroup analyses. These analyses are not intended to demonstrate efficacy in particular subgroups.

Adapted from Loibl S, et al. 2016.2
Data cut-off date: March 16, 2015.
*Evaluated according to RECIST Version 1.1.
3 †Pre-/peri-menopausal patients enrolled in PALOMA-3 received the LHRH agonist goserelin for at least 4 weeks prior to and for the duration of the trial.2

CI = confidence interval; FUL = fulvestrant; HR = hazard ratio; LHRH = luteinising hormone-releasing hormone; = number of patients; NE = not estimable; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors.


​​​​​​​References  
  1. IBRANCE® (Palbociclib) Prescribing Information. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=12240. Accessed September 17, 2021.
  2. Loibl S, et al. Oncologist. 2017;22(9):1028-1038.
  3. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.

​​​​​​​

Support and Services


Learn more ► 
Learn more ► 
Learn more ► 
All rights reserved. Date of preparation: June 2020 PP-IBR-GLB-0254

​​​​​​​Intended for Healthcare Professionals only.

© 2021 Pfizer Pte Ltd. All rights reserved.


The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.